1,383
Views
16
CrossRef citations to date
0
Altmetric
Laboratory Study

The protective role of G protein-coupled estrogen receptor 1 (GPER-1) on methotrexate-induced nephrotoxicity in human renal epithelium cells

, , &
Pages 686-692 | Received 10 Dec 2015, Accepted 08 Feb 2016, Published online: 16 Mar 2016

References

  • Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clinical use of methotrexate. N Engl J Med. 1983;309:1094–1104.
  • Kolli VK, Abraham P, Isaac B, Selvakumar D. Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage. Chemotherapy 2009;55:83–90.
  • Hempel L, Misselwitz J, Fleck C, et al. Influence of high-dose methotrexate therapy (HD-MTX) on glomerular and tubular kidney function. Med Pediatr Oncol. 2003;40:348–354.
  • Izzedine H, Launay-Vacher V, Karie S, Caramella C, de Person F, Deray G. Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol. 2005;64:315–319.
  • Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem. 1999;32:519–536.
  • Ibrahim MA, El-Sheikh AA, Khalaf HM, Abdelrahman AM. Protective effect of peroxisome proliferator activator receptor (PPAR)-alpha and -gamma ligands against methotrexate-induced nephrotoxicity. Immunopharmacol Immunotoxicol. 2014;36:130–137.
  • Morsy MA, Ibrahim SA, Amin EF, Kamel MY, Rifaai RA, Hassan MK. Curcumin ameliorates methotrexate-induced nephrotoxicity in rats. Adv Pharmacol Sci. 2013;2013:387071.
  • Abdel-Raheem IT, Khedr NF. Renoprotective effects of montelukast, a cysteinyl leukotriene receptor antagonist, against methotrexate-induced kidney damage in rats. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:341–353.
  • Gressier B, Lebegue S, Brunet C, et al. Pro-oxidant properties of methotrexate: Evaluation and prevention by an anti-oxidant drug. Pharmazie 1994;49:679–681.
  • Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000;14:1649–1660.
  • Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307:1625–1630.
  • Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7:715–726.
  • Mizukami Y. In vivo functions of GPR30/GPER-1, a membrane receptor for estrogen: From discovery to functions in vivo. Endocr J. 2010;57:101–107.
  • Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, Chappell MC. Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology. 2009;150:3753–3758.
  • Kurt AH, Buyukafsar K. Vasoconstriction induced by G1, a G-protein-coupled oestrogen receptor1 (GPER-1) agonist, in the isolated perfused rat kidney. Eur J Pharmacol. 2013;702:71–78.
  • Kurt AH, Tiftik RN, Un I, Ulker S, Buyukafsar K. G protein-coupled estrogen receptor1 (GPER1) may mediate Rho-kinase (ROCK-2) up-regulation in coronary endothelial cells. Endocr Regul. 2013;47:75–84.
  • Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol. 2006;2:207–212.
  • Prossnitz ER, Sklar LA, Oprea TI, Arterburn JB. GPR30: A novel therapeutic target in estrogen-related disease. Trends Pharmacol Sci. 2008;29:116–123.
  • Chan QK, Lam HM, Ng CF, et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010;17:1511–1523.
  • Chen JQ, Cammarata PP, Baines CP, Yager JD. Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochim Biophys Acta. 2009;1793:1540–1570.
  • Baylis C. Sexual dimorphism in the aging kidney: Differences in the nitric oxide system. Nat Rev Nephrol. 2009;5:384–396.
  • Chin M, Isono M, Isshiki K, et al. Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice. Am J Pathol. 2005;166:1629–1636.
  • Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: A meta-analysis. J Am Soc Nephrol. 2000;11:319–329.
  • Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265–275.
  • Fridovich I. Superoxide radical: An endogenous toxicant. Annu Rev Pharmacol Toxicol. 1983;23:239–257.
  • Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
  • Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28:521–574.
  • Calippe B, Douin-Echinard V, Delpy L, et al. 17Beta-estradiol promotes TLR4-triggered proinflammatory mediator production through direct estrogen receptor alpha signaling in macrophages in vivo. J Immunol. 2010;185:1169–1176.
  • Calippe B, Douin-Echinard V, Laffargue M, et al. Chronic estradiol administration in vivo promotes the proinflammatory response of macrophages to TLR4 activation: Involvement of the phosphatidylinositol 3-kinase pathway. J Immunol. 2008;180:7980–7988.
  • Pektaş M, Kurt AH, Un I, Tiftik RN, Buyukafsar K. Effects of 17β-estradiol and progesterone on the production of adipokines in differentiating 3T3-L1 adipocytes: Role of Rho-kinase. Cytokine. 2015;72:130–134.
  • Cho L. Estrogen raises risk of blood clots and stroke. Replacing this powerful hormone after menopause has more risks than first thought. Heart Advis. 2008;11:7.
  • Lekontseva O, Chakrabarti S, Jiang Y, Cheung CC, Davidge ST. Role of neuronal nitric-oxide synthase in estrogen-induced relaxation in rat resistance arteries. J Pharmacol Exp Ther. 2011;339:367–375.
  • Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995;332:1589–1593.
  • Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med. 2000;160:2263–2272.
  • Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012;7:CD004143.
  • Hazell GG, Yao ST, Roper JA, Prossnitz ER, O’Carroll AM, Lolait SJ. Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues. J Endocrinol. 2009;202:223–236.
  • Esqueda ME, Craig T, Hinojosa-Laborde C. Effect of ovariectomy on renal estrogen receptor-alpha and estrogen receptor-beta in young salt-sensitive and -resistant rats. Hypertension. 2007;50:768–772.
  • Sanden C, Broselid S, Cornmark L, et al. G protein-coupled estrogen receptor 1/G protein-coupled receptor 30 localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments. Mol Pharmacol. 2011;79:400–410.
  • Yang YH, Ngo D, Jones M, Simpson E, Fritzemeier KH, Morand EF. Endogenous estrogen regulation of inflammatory arthritis and cytokine expression in male mice, predominantly via estrogen receptor alpha. Arthritis Rheum. 2010;62:1017–1025.
  • Lafferty AR, Torpy DJ, Stowasser M, et al. A novel genetic locus for low renin hypertension: Familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet. 2000;37:831–835.
  • Ariazi EA, Brailoiu E, Yerrum S, et al. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010;70:1184–1194.
  • Wang C, Lv X, Jiang C, Davis JS. The putative G-protein coupled estrogen receptor agonist G-1 suppresses proliferation of ovarian and breast cancer cells in a GPER-independent manner. Am J Transl Res. 2012;4:390–402.
  • Duckles SP, Krause DN, Stirone C, Procaccio V. Estrogen and mitochondria: A new paradigm for vascular protection? Mol Interv. 2006;6:26–35.
  • Klinge CM. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem. 2008;105:1342–1351.
  • Mattingly KA, Ivanova MM, Riggs KA, Wickramasinghe NS, Barch MJ, Klinge CM. Estradiol stimulates transcription of nuclear respiratory factor-1 and increases mitochondrial biogenesis. Mol Endocrinol. 2008;22:609–622.
  • Stirone C, Duckles SP, Krause DN, Procaccio V. Estrogen increases mitochondrial efficiency and reduces oxidative stress in cerebral blood vessels. Mol Pharmacol. 2005;68:959–965.
  • Razmara A, Sunday L, Stirone C, et al. Mitochondrial effects of estrogen are mediated by estrogen receptor alpha in brain endothelial cells. J Pharmacol Exp Ther. 2008;325:782–790.
  • Guo J, Krause DN, Horne J, Weiss JH, Li X, Duckles SP. Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro. J Cereb Blood Flow Metab. 2010;30:545–554.
  • Jahovic N, Cevik H, Sehirli AO, Yeğen BC, Sener G. Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res. 2003;34:282–287.
  • Taylor AH, Al-Azzawi F. Immunolocalisation of oestrogen receptor beta in human tissues. J Mol Endocrinol. 2000;24:145–155.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.